Who is sponsoring NCT05608213?

NCT05608213 is sponsored by Second Affiliated Hospital of Guangzhou Medical University.

What condition does NCT05608213 study?

NCT05608213 studies Hepatocellular Carcinoma Non-resectable.

Is NCT05608213 still recruiting?

NCT05608213 is currently recruiting now. Last updated 8 November 2022.

Last reviewed 2022-11-08 · How we verify

NCT05608213

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Recruiting now Phase 3 Last updated 8 November 2022

What this trial tests

Phase 3 trial testing Lenvatinib Plus I-125 Seed Brachytherapy in Hepatocellular Carcinoma Non-resectable in 187 participants. Currently enrolling.

Timeline

2 November 2022

Primary endpoint
31 October 2026

1 December 2026

Quick facts

Lead sponsor	Second Affiliated Hospital of Guangzhou Medical University
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	187
Start date	2 November 2022
Primary completion	31 October 2026
Estimated completion	1 December 2026
Sites	1 location across China

Drugs / interventions tested

Lenvatinib Plus I-125 Seed Brachytherapy
Lenvatinib (LENVATINIB) — full drug profile →

Conditions studied

Hepatocellular Carcinoma Non-resectable — all drugs for Hepatocellular Carcinoma Non-resectable →

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma Non-resectable. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is conducted to evaluate the efficacy and safety of lenvatinib plus iodine-125 seed brachytherapy (Len-I) compared with lenvatinib (Len) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Hepatocellular carcinoma: signaling pathways and therapeutic advances.
Zheng J, Wang S, Xia L, Sun Z, et al · · 2025 · cited 142× · PMID 39915447 · DOI 10.1038/s41392-024-02075-w
Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study.
Guo Y, Wu J, Liang L, Zhu K, et al · · 2023 · cited 4× · PMID 37749616 · DOI 10.1186/s40644-023-00604-4

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma Non-resectable

Currently open trials in the same condition.

NCT06904183 — Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT · Phase 2 · recruiting
NCT06904196 — Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC · Phase 2 · recruiting
NCT06561399 — Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) · recruiting
NCT06492395 — Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT · Phase 3 · recruiting
NCT06397235 — DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC · Phase 2 · recruiting

Other Second Affiliated Hospital of Guangzhou Medical University trials

Trials by the same sponsor.

NCT06966830 — Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus · not yet recruiting
NCT06936683 — Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia（the HSV-SP Study） · not yet recruiting
NCT07374328 — Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus · Phase 1, PHASE2 · recruiting
NCT06904183 — Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT · Phase 2 · recruiting
NCT06904196 — Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05608213 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Guangzhou Medical University
Last refreshed: 8 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05608213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing